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THIS ISSUE’S AUTHORS 
LINDA CHANG, M.D., is professor of medi­
cine at the John A. Burns School of Medicine at 
the University of Hawaii and codirector of the 
University of Hawaii–Queen’s Medical Center 
Magnetic Resonance Research Program. She has 
extensive experience in clinical neuroscience 
research, particularly in the application of advanced 
neuroimaging techniques to study brain changes 
associated with HIV infection, substance abuse, 
brain development, and aging. Dr. Chang serves 
on the Science & Practice Perspectives Editorial 
Board. 
DONALD F. DANSEREAU, PH.D., is profes­
sor of psychology at Texas Christian University in 
Fort   Worth and the associate director for cogni­
tive interventions at the Institute of Behavioral 
Research. His publications include more than 160 
papers that focus primarily on cognitive approaches 
for improving education, motivation, and engage­
ment in drug treatment interventions. His cur­
rent interests include the development of theo­
retical models and practical strategies for acquiring 
and using complex information, especially in orga­
nizational settings. 
JOANNA S. FOWLER, PH.D., is a senior chemist 
at Brookhaven National Laboratory and director 
of the Brookhaven Center for Translational 
Neuroimaging. Her research interests include 
rapid organic synthesis and radiotracer design and 
development for imaging-specific molecular 
targets, imaging monoamine oxidase in studies of 
the effects of tobacco smoke exposure on the human 
brain and peripheral organs, and the use of positron 
emission tomography to study drug pharmaco­
kinetics and pharmacodynamics. 
JAY M. HANSEN is executive director of Prairie 
Ridge Addiction Treatment Services. He has guided 
the organization through program planning and 
development, facility development and reloca­
tion, initial and ongoing licensure, a transition to 
managed care, and community engagement. Most 
recently, Mr. Hansen has spearheaded the agency’s 
continuous quality improvement effort. He is an 
active member of the Iowa Substance Abuse Pro­
gram Directors’ Association, which is working to 
improve the community-based prevention and 
treatment system in Iowa. Mr. Hansen has more 
than 30 years of experience in the substance abuse 
prevention and treatment field. 
CHERYL A. KASSED, PH.D., M.S.P.H., is a 
senior research leader, writer, and editor at Thomson 
Medstat, Inc. She focuses on co-occurring sub­
stance abuse and mental illness, advances in phar­
macology, adolescent brain development, and 
dementias. Dr. Kassed has more than 15 years 
of bench science and data analysis experience. 
FRANK McCORRY, PH.D., is director of the 
Practice Improvement and Performance Unit at 
the New York State Office of Alcoholism and 
Substance Abuse Services. He is responsible for 
clinical policy and practice improvement issues, 
particularly in the areas of public health, co­
occurring mental health and addictive disorders, 
and managed care. He is the principal investiga­
tor for a NIDA State infrastructure grant to enhance 
New York’s capacity to foster the adoption of 
evidence-based practices. Dr. McCorry is chair of 
the Washington Circle Group, an initiative spon­
sored by the Substance Abuse and Mental Health 
Services Administration to develop substance 
abuse performance measures for use in managed 
care and public sector settings. He also is co-chair 
of the National Quality Forum’s Evidence-Based 
Practices to Treat Substance Use Disorders Steering 
Committee. 
CONALL M. O’CLEIRIGH, PH.D., is a clin­
ical fellow in psychology at Massachusetts General 
Hospital/Harvard Medical School and a behav­
ioral scientist at the Fenway Institute. His areas 
of research interest include adapting cognitive-
behavioral therapy to address issues of depression 
and treatment adherence. His current projects 
include developing and testing treatments to 
address primary and secondary prevention issues 
associated with HIV. 
MICHAEL W. OTTO, PH.D., is professor of 
psychology at Boston University and director of 
the Center for Anxiety and Related Disorders. Dr. 
Otto conducts intervention and translational 
research projects targeting a wide range of affec­
tive and substance use disorders. His current proj­
ects include NIDA-funded treatment outcome 
investigations of novel cognitive-behavioral treat­
ment strategies, including medication augmen­
tation strategies, for substance use disorders. 
MARK H. POLLACK, M.D., is director of the 
Center for Anxiety and Traumatic Stress Disorders 
at Massachusetts General Hospital and associate 
professor of psychiatry at Harvard Medical School. 
His areas of clinical and research interest include 
the acute and long-term course, pathophysiology, 
and treatment of patients with anxiety disorders, 
substance dependence, and associated comor­
bidities. Dr. Pollack has been funded by NIDA 
for investigations of novel treatment strategies for 
central nervous system correlates of chronic sub­
stance dependence. 
D. DWAYNE SIMPSON, PH.D., is director 
of the Institute of Behavioral Research and the 
S.B. Sells Professor of Psychology at Texas Christian 
University in Fort  Worth. His work is reported in 
more than 250 publications and includes sev­
eral large-scale and longitudinal national evalu­
ations. It now focuses on treatment process (includ­
ing the integration of client assessments and strategic 
interventions), the transfer of research to prac­
tice, and the role of organizational functioning in 
treatment improvement. He is a fellow in the 
American Psychological Association and the 
American Psychological Society, and an interna­
tional advisor on drug abuse treatment and related 
policy issues. 
NORA D. VOLKOW, M.D., is director of the 
National Institute on Drug Abuse and is an inter­
national leader in drug addiction research and 
brain imaging. Dr. Volkow came to NIDA from 
Brookhaven National Laboratory, where she held 
concurrent positions as associate director for life 
sciences, director of nuclear medicine, and direc­
tor of the NIDA–Department of Energy Regional 
Neuroimaging Center. In addition, Dr. Volkow 
was a professor in the Department of Psychiatry 
and associate dean of the medical school at the 
State University of New York–Stony Brook. At 
Brookhaven, Dr. Volkow was the first to use imag­
ing to investigate neurochemical changes that 
occur during drug addiction. She investigated the 
neurochemical mechanisms that influence the 
way individuals respond to drugs of abuse and the 
potential link to vulnerability to drug abuse, alco­
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PETER BANYS, M.D., is a health sciences clin­
ical professor of psychiatry at the University of 
California, San Francisco (UCSF). He is director 
of the substance abuse programs at the Veterans 
Affairs (VA) Medical Center and director of the 
VA/UCSF Substance Abuse Physician Fellowship 
Program. He is a past president of the California 
Society of Addiction Medicine and a member of 
the executive board of the American Society of 
Addiction Medicine. He recently returned from 
Vietnam, where he consulted with health officials 
about the intersecting epidemics of HIV infec­
tion and injection drug use. 
LINDA BRADSHAW, M.A., is a program man­
ager at Changepoint, Inc., in Portland, Oregon. 
She has been working in the addiction treatment 
and prevention field since 1973. For the past 20 
years, she has been assisting agencies in obtaining 
and maintaining their State certifications and 
accreditations from the Joint Commission on 
Accreditation of Healthcare Organizations and 
the Commission on Accreditation of Rehabilita­
tion Facilities. She has supervised a wide contin­
uum of services, from outpatient to residential, 
for both adolescent and adult populations. 
FELIPE CASTRO, M.S.W., PH.D., is professor 
of clinical psychology in the Department of 
Psychology, Arizona State University. Dr. Castro’s 
research areas include the study of substance abuse 
risk and protective factors, especially those hav­
ing a cultural origin, and the design of prevention 
and treatment interventions for racial/ethnic 
minorities. He is particularly interested in factors 
that promote successful recovery from addic­
tion to stimulants, including methamphetamine 
and cocaine. Dr. Castro also serves as an associ­
ate editor for the journals Prevention Science and 
American Journal of Public Health. 
DEBORAH GARNICK, SC.D., is a professor at 
the Institute for Behavioral Health at The Heller 
School for Social Policy and Management at 
Brandeis University and associate dean of aca­
demic personnel. Dr. Garnick leads the Brandeis 
team in a collaboration to specify the national out­
come measures for behavioral health in a project 
funded by the Substance Abuse and Mental Health 
Services Administration. She also directs an effort 
to extend performance measures for substance 
abuse services developed for commercial managed 
care plans to public health systems through research 
grants funded by NIDA and the National Institute 
on Alcohol Abuse and Alcoholism. In addition, 
she is a member of the Washington Circle Group 
and leads their work group on public sector per­
formance measures for substance abuse.  
DANIEL R. KIVLAHAN, PH.D., is director of 
the U.S. Department of Veterans Affairs (VA) 
National Center of Excellence in Substance Abuse 
Treatment and Education at the VA Puget Sound 
Health Care System, where he has been an addic­
tion treatment clinician and investigator since 
1985. He is an associate professor in the Department 
of Psychiatry and Behavioral Sciences at the 
University of Washington and clinical coordina­
tor of the VA Substance Use Disorder Quality 
Enhancement Research Initiative. He has been 
actively involved in developing national per­
formance measures. Among his recent publica­
tions are reports from the COMBINE Study for 
treatment of alcohol dependence and several other 
reports on alcohol screening in primary care set­
tings, including validation of the AUDIT-C. 
MICHAEL LEVY, PH.D., is a licensed psychol­
ogist who has worked for more than 20 years with 
clients who suffer from substance abuse and other 
disorders. He has directed locked inpatient psy­
chiatric units, including one for clients with co­
occurring disorders, and has clinically managed 
and overseen quality improvement processes for 
detoxification, outpatient, and other substance 
abuse treatment programs. He has also written 
numerous articles and book chapters and has con­
ducted workshops on working with substance-
abusing clients. 
PAUL LINDE, M.D., is associate clinical pro­
fessor of psychiatry at the University of California, 
San Francisco School of Medicine and an attend­
ing psychiatrist in the Psychiatric Emergency 
Services and the STOP and Stonewall outpatient 
stimulant addiction clinics at San Francisco General 
Hospital. Author of a nonfiction book entitled 
Of Spirits and Madness: An American Psychiatrist 
in Africa, published in 2002, Dr. Linde is prepar­
ing his next book, Danger to Self: The Making of 
a 21st Century Psychiatrist, for publication by the 
University of California Press in 2008. 
BAYLEY RAIZ, L.C.S.W., M.B.A., is director of 
research and quality improvement at Walden 
House, Inc., one of California’s largest behavioral 
health and human services providers. Mr. Raiz 
has 8 years of experience as a therapist, supervi­
sor, manager, and consultant in a variety of behav­
ioral health areas and has successfully overseen 
quality improvement at various organizations. 
RICHARD A. RAWSON, PH.D., is associate 
director of the Integrated Substance Abuse Programs 
at the University of California, Los Angeles School 
of Medicine. Dr. Rawson has been a member of 
the UCLA Department of Psychiatry for more 
than 20 years. He oversees a portfolio of addic­
tion research ranging from brain imaging studies 
to numerous clinical trials on pharmacological 
and psychosocial addiction treatments, as well as 
the study of how new treatments are applied in 
the treatment system. During the past decade, he 
has worked with the U.S. State Department on 
large substance abuse research and treatment proj­
ects that export U.S. technology and addiction 
science to Mexico, Thailand, Israel, Egypt, and 
the Palestinian Authority. Dr. Rawson serves on 
the Science & Practice Perspectives Editorial Board. 
EWA STAMPER, PH.D., is a clinical psychol­
ogist and a member of the Hawaii Psychological 
Association. Dr. Stamper is in private practice 
in Kailua, Hawaii. Her areas of expertise include 
substance abuse, trauma, and depression. 